Bruce Morimoto
head drug dev Fuku Biotech
Seminars
Wednesday 4th February 2026
Panel Discussion: Ushering in a New Era of Disease-Modifying Therapies in AD & PD – Beyond Amyloid & α-Synuclein
8:30 am
- Exploring emerging mechanisms such as mitochondrial stress, ferroptosis, and microglial TREM2 to diversify therapeutic strategies and expand opportunities
- Evaluating how mixed-modality combinations may outperform single antibodies, offering more robust and durable disease-modifying potential
- Implementing biomarker panels to de-risk first-in-human trials, enabling smarter patient selection and stronger regulatory confidence
Thursday 5th February 2026
Panel Discussion: Genetics-Guided Risk Talks & Real-World Barriers: Driving Smarter Uptake of Disease-Modifying Therapies in Neurodegeneration
9:00 am
- Weighing how genetic risk factors such as APOE-ε4 in Alzheimer’s and LRRK2, GBA, or Parkin variants in Parkinson’s influence both treatment response and side-effect risk to help clinicians and patients make more informed therapy choices
- Examining real-world barriers to uptake of novel disease-modifying therapies across Alzheimer’s and Parkinson’s, including safety concerns (e.g., ARIA or off-target toxicities), monitoring burden, cost, and modest efficacy to highlight what truly drives or limits prescription and patient acceptance
- Knowing that earlier intervention before symptoms offers the greatest potential benefit, what screening or risk‑scoring approaches could expand pre‑symptomatic use while keeping the risk‑benefit ratio acceptable?
Thursday 5th February 2026
Panel Discussion: Bridging Innovation & Investment: De-Risking Disease-Modifying Neurodegenerative Therapies to Secure Investor Backing
4:30 pm
- How important is it to present rigorously validated biology and clear platform expansion potential, rather than a single asset story, when seeking investment in disease modifying Alzheimer’s or Parkinson’s therapies?
- Is a biomarker driven proof of concept within roughly 24 months now viewed as the standard benchmark for funding decisions in neurodegenerative drug development?
- To what extent does a pipeline that hedges risk through multiple mechanisms, such as combining blood–brain barrier shuttle antibodies with gene or small molecule therapies, shape investment appetite in this space?
Thursday 5th February 2026
Chair’s Opening Remarks
8:30 am
Wednesday 4th February 2026
Chair’s Opening Remarks
8:25 am
Thursday 5th February 2026
Chair’s Closing Remarks & End of Conference
5:00 pm
Wednesday 4th February 2026
Chair’s Closing Remarks
5:00 pm
